QT
KNTE

Quantbot Technologies’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Quantbot Technologies’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,700
Closed -$3.78K – 2085
2023
Q3 		$3.78K Sell
2,700
-400
-13% -$961 ﹤0.01% 1459
2023
Q2 		$9.39K Buy
+3,100
New +$12K ﹤0.01% 1468
2022
Q2 		– Sell
-2,400
Closed -$27K – 2246
2022
Q1 		$27K Buy
+2,400
New +$26.4K ﹤0.01% 1320

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Quantbot Technologies's KNTE Position: Q4 2023 in Review

Quantbot Technologies sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q4 2023, closing a stake of 2,700 shares — an estimated $3.78K sold.

Quantbot Technologies first reported a position in KNTE in Q1 2022 and held it in 3 quarters. The position peaked at $27K in Q1 2022. 62 funds tracked by Wall St. Rank hold KNTE as of Q4 2023.

  • Quantbot Technologies reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Quantbot Technologies sold 2,700 Kinnate Biopharma Inc. Common Stock shares in Q4 2023, an estimated $3.78K.
  • Quantbot Technologies first reported a position in Kinnate Biopharma Inc. Common Stock in Q1 2022 and held it in 3 quarters.
  • Quantbot Technologies's Kinnate Biopharma Inc. Common Stock position peaked at $27K in Q1 2022.
  • 62 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q4 2023.

Based on Quantbot Technologies's 13F filing for Q4 2023, filed 14 Feb 2024.